Will the future of pharmacovigilance be more automated?

Journal: Expert opinion on drug safety
Published Date: Jul 12, 2023

Abstract

INTRODUCTION: Artificial intelligence (AI) based tools offer new opportunities for pharmacovigilance (PV) activities. Nevertheless, their contribution to PV needs to be tailored to preserve and strengthen medical and pharmacological expertise in drug safety.

Authors

  • Francesco Salvo
    INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, Bordeaux, France.
  • Joëlle Micallef
    CRPV Marseille Provence Corse, Service Hospitalo-Universitaire de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Amir Lahouegue
    Pharmacovigilance et information médicale, AstraZeneca, 92400 Courbevoie, France.
  • Laurent Chouchana
    Service de pharmacologie, centre-université Paris Cité, centre régional de pharmacovigilance, hôpital Cochin, AP-HP, 75014 Paris, France.
  • Louis Létinier
    INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, Bordeaux, France.
  • Jean-Luc Faillie
    Inserm, Departement de Pharmacologie Medicale Et Toxicologie, Centre Regional de PV, Institut Desbrest D'epidemiologie Et de Sante Publique, CHU de Montpellier, Universite Montpellier, Montpellier, France.
  • Antoine Pariente
    INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, Bordeaux, France.

Keywords

External Resources

Popular Topics
Recent Journals